A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1
Brief description of study
If you have been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) you may qualify for this Phase 3 study. The main goal of this study is to evaluate the effectiveness of the addition of an investigational drug called enzastaurin to standard first line chemotherapy in patients with Diffuse Large B-Cell Lymphoma (DLBCL).
Clinical Study Identifier: s17-01110
ClinicalTrials.gov Identifier: NCT03263026
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
